Oligonucleotide Synthesis Market Updates

Skyquest Technology's expert advisors continuously track and analyze the latest developments and updates related to oligonucleotide synthesis market. Our team of analysts stay abreast of all the recent news stories shaping the industry including new product launches by major companies, strategic partnerships, M&As, Patent filings and industry and regulatory developments.

Oligonucleotide Synthesis Market News

  • In November 2023, Twist Bioscience Corporation (NASDAQ: TWST), known for its high-quality synthetic DNA produced using its silicon platform, introduced Twist Express Genes, a premier gene synthesis service boasting an order-to-shipping turnaround time of five to seven business days. 
  • In October 2023, Integrated DNA Technologies (IDT), a leading provider of genomics solutions, announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa. This marks a significant milestone in IDT's 35-year history, as it marks the company's entry into the therapeutics space. The new facility enables IDT to manufacture products ranging from research-grade to current good manufacturing practice (cGMP) grade cell and gene therapy reagents. This allows researchers to partner with IDT as a single provider to facilitate a seamless transition from laboratory research to therapeutic development. 
  • In September 2023, Integrated DNA Technologies (IDT) and Aldevron, prominent CRISPR gene editing companies, finalized a new global distribution agreement aimed at broadening essential CRISPR solutions for cell and gene therapy clients. Starting immediately, IDT will carry and offer three additional CRISPR nucleases for research use only (RUO) and current good manufacturing practice (cGMP) applications. These nucleases, manufactured by Aldevron, come with distinct performance attributes, providing researchers with an expedited route to clinical applications.

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Oligonucleotide Synthesis Market size was valued at USD 7.3 Billion in 2023 and is poised to grow from USD 8.57 Billion in 2024 to USD 30.88 Billion by 2032, growing at a CAGR of 17.4% during the forecast period (2025-2032).

Investing in the development of oligonucleotide synthesis for different disease indications should remain the prime focus of all companies. Reducing the costs of synthesis will be a major area of interest for all oligonucleotide synthesis providers to improve their profitability. Utilizing supportive government initiatives and funding to maximize R&D scope will also be a popular strategy for oligonucleotide synthesis market players in the future.  'Danaher Corporation ', 'Thermo Fisher Scientific Inc. ', 'Merck KGaA ', 'Eurofins Scientific ', 'Agilent Technologies, Inc. ', 'Kaneka Corporation ', 'Azenta, Inc. ', 'Sarepta Therapeutics, Inc. ', 'AstraZeneca ', 'Astellas Pharma Inc. ', 'Jazz Pharmaceuticals PLC ', 'Nippon Shinyaku, Co. Ltd. (NS Pharma, Inc.) ', 'Ionis Pharmaceuticals, Inc. ', 'Novartis AG ', 'OligoMaker ApS (Part of TAG Copenhagen A/S) ', 'Biolegio BV ', 'Biolytic Lab Performance, Inc. ', 'Bio-Synthesis, Inc. ', 'Creative Biogene ', 'Reprocell, Inc.'

Oligonucleotides play a key role in diagnostic tools such as PCR, qPCR, and next-generation sequencing (NGS) and demand for early diagnostics is increasing rapidly. This factor is projected to create new opportunities for oligonucleotide synthesis market growth going forward. 

Use of AI and Automation: Automation and artificial intelligence are being integrated into oligonucleotide synthesis processes, to enhance the accuracy and scalability of the process. Automated synthesizers and AI-driven design tools are projected to be highly popular as they can assist in cost reduction as well.  

North America is projected to account for a dominant oligonucleotide synthesis market share. The presence of a strong medical research infrastructure, supportive government funding for research, and rising use of genetic treatments are helping this region maintain its high market share. The United States and Canada are estimated to be the leading markets in this region as incidence of chronic diseases rises in these countries. The presence of leading pharmaceutical and biotechnology companies will also promote the demand for oligonucleotide synthesis in this region.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Oligonucleotide synthesis Market
Oligonucleotide Synthesis Market

Report ID: SQMIG35H2107

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE